These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 37262395)

  • 21. Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma.
    Dharmani C; Unni S; Pham N; Shaikh NF; Xiong Y; Vashi R; Fofah O; Strubing A; Salas M; Tu N; Wooddell M; Zhou X; Near A
    Future Oncol; 2024 May; 20(15):1013-1030. PubMed ID: 37814886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the Treatment of Anaplastic Large Cell Lymphoma.
    Vu K; Ai W
    Curr Hematol Malig Rep; 2018 Apr; 13(2):135-141. PubMed ID: 29516333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year results from the ECHELON-2 trial.
    Burke JM; Yu KS; Mordi U; Bloudek B; Liu N; Phillips T
    J Manag Care Spec Pharm; 2023 Mar; 29(3):314-323. PubMed ID: 36840956
    [No Abstract]   [Full Text] [Related]  

  • 24. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
    Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
    Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Treatment of Peripheral T-cell Lymphoma.
    Stuver R; Epstein-Peterson ZD; Johnson WT; Khan N; Lewis N; Moskowitz AJ; Sauter CS; Horwitz S
    Oncology (Williston Park); 2022 May; 36(5):293-305. PubMed ID: 35576176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
    Zain JM
    Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapies for peripheral T-cell lymphomas.
    Savage KJ
    Hematology Am Soc Hematol Educ Program; 2011; 2011():515-24. PubMed ID: 22160083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.
    Nizamuddin I; Galvez C; Pro B
    Semin Hematol; 2021 Apr; 58(2):85-94. PubMed ID: 33906726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current treatment strategies for peripheral T-cell lymphoma].
    Munakata W
    Rinsho Ketsueki; 2021; 62(8):1112-1120. PubMed ID: 34497198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry.
    Kida S; Fuji S; Morishima T; Nakata K; Miyashiro I; Ishikawa J
    Int J Hematol; 2021 Aug; 114(2):246-251. PubMed ID: 33864237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
    Horwitz S; O'Connor OA; Pro B; Illidge T; Fanale M; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Lennard A; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Iyer S; Zinzani PL; Hua Z; Little M; Rao S; Woolery J; Manley T; Trümper L;
    Lancet; 2019 Jan; 393(10168):229-240. PubMed ID: 30522922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL.
    Feldman T; Zou D; Rebeira M; Lee J; Fanale M; Manley T; Rao S; Feliciano J; Harris M; Kansal A
    Am J Manag Care; 2020 Feb; 26(2):e41-e49. PubMed ID: 32059099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CHOEP-21 chemotherapy for newly diagnosed nodal peripheral T-cell lymphomas (PTCLs) in Maharaj Nakorn Chiang Mai Hospital.
    Rattarittamrong E; Norasetthada L; Tantiworawit A; Chai-Adisaksopha C; Nawarawong W
    J Med Assoc Thai; 2013 Nov; 96(11):1416-22. PubMed ID: 24428090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
    Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
    Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of long-term clinical outcomes of CHOP chemotherapy between Japanese patients with nodal peripheral T-cell lymphomas and those with diffuse large B-cell lymphoma in the study group of the Tohoku Hematology Forum.
    Akagi T; Takahashi N; Yamaguchi K; Ishizawa K; Murai K; Tajima K; Ikeda K; Kameoka Y; Kameoka J; Ito S; Kato Y; Noji H; Shichishima T; Itoh J; Ichinohasama R; Harigae H; Ishida Y; Sawada K
    J Clin Exp Hematop; 2011; 51(1):29-35. PubMed ID: 21628858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
    Svoboda J; Bair SM; Landsburg DJ; Dwivedy Nasta S; Nagle SJ; Barta SK; Khan N; Filicko-O'Hara J; Gaballa S; Strelec L; Chong E; Mitnick S; Waite TS; King C; Ballard H; Youngman M; Gerson J; Plastaras JP; Maity A; Bogusz AM; Hung SS; Nakamura H; Nejati R; Steidl C; Lim M; Ruella M; Schuster SJ
    Haematologica; 2021 Jun; 106(6):1705-1713. PubMed ID: 32414850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management.
    Armitage JO
    Am J Hematol; 2012 May; 87(5):511-9. PubMed ID: 22508369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.
    Prochazka V; Faber E; Raida L; Vondrakova J; Kucerova L; Jarosova M; Indrak K; Papajik T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):63-6. PubMed ID: 19365529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma.
    Beaven AW; Diehl LF
    Hematology Am Soc Hematol Educ Program; 2015; 2015():550-8. PubMed ID: 26637771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic and prognostic implications of tumor expression of the GATA-3 gene in nodal peripheral T-cell lymphoma (nPTCL): Retrospective data from a Latin American cohort.
    de Pádua Covas Lage LA; Brito CV; Levy D; Culler HF; Freitas Couto SC; de Oliveira LBA; Nogueira Zerbini MC; Rocha V; Pereira J
    Leuk Res; 2022 Mar; 114():106794. PubMed ID: 35131666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.